Physician profile
Sumathy Reddy
NPI 1992871032
$3,703.43
in general payments reported to CMS, 2019-2025
14 companies · $820 in 2025
The $820 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $139 · 2021: $341 · 2022: $448 · 2023: $558 · 2024: $1,018 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,144.55 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $498.42 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $459.18 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $432.96 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Allergan, INC. | $279.17 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $260.73 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.78 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $140.65 | 2021 | |
| Abbvie INC. | $86.08 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $61.33 | 2024-2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $56.76 | 2019-2022 | |
| Amgen INC. | $45.49 | 2025 | Repatha |
| Janssen Pharmaceuticals, INC | $37.48 | 2023 | Invega Trinza, Invega Sustenna |
| Almatica Pharma LLC | $22.85 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumathy Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.